Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLCN2 | P51788 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5861888 | 0.86 | FOLH1 (0.43) | CLCN2TSHRALDH1A1TP53HTT | |
| SCHEMBL29344686 | 0.85 | CLCN2 (0.42) | CLCN2GABRA1GABRB2TSHRF2R | |
| SCHEMBL8814289 | 0.82 | CLCN2 (0.40) | CLCN2GABRA1GABRB2TSHRF2R | |
| SCHEMBL8995207 | 0.82 | CLCN2 (0.40) | CLCN2GABRA1GABRB2TSHRF2R | |
| SCHEMBL8814283 | 0.82 | CLCN2 (0.40) | CLCN2GABRA1GABRB2TSHRF2R | |
| SCHEMBL11412880 | 0.80 | GABRA1 (0.44) | CLCN2GABRA1GABRB2TSHRF2R | |
| SCHEMBL2935940 | 0.79 | GABRA1 (0.48) | CLCN2GABRA1GABRB2TSHRF2R | |
| SCHEMBL7991056 | 0.79 | NPSR1 (0.39) | CLCN2GABRA1GABRB2TSHRF2R | |
| SCHEMBL7987828 | 0.79 | CLCN2 (0.38) | CLCN2GABRA1GABRB2TSHRF2R | |
| SCHEMBL49956 | 0.77 | TSHR (0.50) | CLCN2GABRA1GABRB2TSHRF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094516-B2 | Benzobisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1180765-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS INC (JP) | 2005-04-06 | — | — | EP | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-6627288-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS, INC. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | CLCN2 523/4885GABRA1 140/4885GABRB2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.